 Jochen Reiser
Concepts (770)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Podocytes | 93 | 2022 | 171 | 21.250 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 52 | 2022 | 84 | 15.270 |
Why?
| | Glomerulosclerosis, Focal Segmental | 43 | 2019 | 86 | 11.790 |
Why?
| | Proteinuria | 40 | 2021 | 116 | 9.140 |
Why?
| | Kidney Glomerulus | 43 | 2021 | 96 | 6.600 |
Why?
| | Kidney Diseases | 24 | 2021 | 146 | 5.820 |
Why?
| | Renal Insufficiency, Chronic | 13 | 2022 | 103 | 5.030 |
Why?
| | TRPC Cation Channels | 17 | 2018 | 25 | 4.820 |
Why?
| | Animals | 121 | 2022 | 5312 | 4.130 |
Why?
| | Kidney | 24 | 2022 | 210 | 4.120 |
Why?
| | Glomerular Filtration Rate | 14 | 2022 | 77 | 3.560 |
Why?
| | Diabetic Nephropathies | 11 | 2020 | 39 | 3.070 |
Why?
| | Kidney Failure, Chronic | 11 | 2021 | 176 | 2.910 |
Why?
| | Mice | 70 | 2022 | 1894 | 2.900 |
Why?
| | Acute Kidney Injury | 7 | 2022 | 64 | 2.590 |
Why?
| | Nephrotic Syndrome | 15 | 2020 | 38 | 2.430 |
Why?
| | Humans | 156 | 2022 | 31481 | 2.370 |
Why?
| | Kidney Transplantation | 12 | 2022 | 141 | 2.320 |
Why?
| | Signal Transduction | 29 | 2022 | 588 | 1.990 |
Why?
| | Actins | 16 | 2019 | 63 | 1.930 |
Why?
| | Membrane Proteins | 21 | 2020 | 230 | 1.790 |
Why?
| | Urokinase-Type Plasminogen Activator | 5 | 2022 | 11 | 1.730 |
Why?
| | Cytoskeleton | 15 | 2019 | 67 | 1.570 |
Why?
| | Mice, Knockout | 18 | 2022 | 399 | 1.420 |
Why?
| | Nephrosis, Lipoid | 7 | 2018 | 15 | 1.380 |
Why?
| | Integrin alphaVbeta3 | 7 | 2021 | 30 | 1.370 |
Why?
| | Homeostasis | 3 | 2021 | 110 | 1.360 |
Why?
| | Albuminuria | 4 | 2017 | 23 | 1.340 |
Why?
| | Cells, Cultured | 27 | 2021 | 802 | 1.330 |
Why?
| | Female | 68 | 2022 | 18253 | 1.260 |
Why?
| | Male | 73 | 2022 | 17583 | 1.260 |
Why?
| | Mice, Inbred C57BL | 19 | 2022 | 548 | 1.240 |
Why?
| | Dynamins | 8 | 2022 | 18 | 1.190 |
Why?
| | Cathepsin L | 6 | 2011 | 15 | 1.160 |
Why?
| | Microfilament Proteins | 9 | 2016 | 33 | 1.130 |
Why?
| | Cytoskeletal Proteins | 6 | 2014 | 34 | 1.110 |
Why?
| | Glomerulonephritis | 4 | 2020 | 27 | 1.100 |
Why?
| | Nephritis | 2 | 2014 | 3 | 1.080 |
Why?
| | Integrin beta3 | 6 | 2020 | 14 | 1.080 |
Why?
| | Lupus Nephritis | 4 | 2015 | 35 | 1.080 |
Why?
| | Diabetes Mellitus | 4 | 2022 | 150 | 1.080 |
Why?
| | Vascular Calcification | 2 | 2021 | 13 | 1.050 |
Why?
| | Immunoconjugates | 2 | 2014 | 13 | 1.050 |
Why?
| | Mice, Transgenic | 13 | 2020 | 308 | 1.020 |
Why?
| | Cathepsins | 3 | 2010 | 11 | 1.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 8 | 2019 | 94 | 1.010 |
Why?
| | Coronary Angiography | 3 | 2020 | 106 | 0.970 |
Why?
| | Phenotype | 10 | 2019 | 379 | 0.940 |
Why?
| | Epithelial Cells | 10 | 2018 | 101 | 0.940 |
Why?
| | MicroRNAs | 4 | 2016 | 63 | 0.920 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2022 | 16 | 0.900 |
Why?
| | Proteins | 8 | 2010 | 94 | 0.870 |
Why?
| | Glomerular Filtration Barrier | 3 | 2020 | 4 | 0.810 |
Why?
| | Apolipoproteins | 2 | 2017 | 11 | 0.800 |
Why?
| | Lipoproteins, HDL | 2 | 2017 | 32 | 0.800 |
Why?
| | Renal Dialysis | 2 | 2021 | 117 | 0.790 |
Why?
| | Immunosuppressive Agents | 10 | 2020 | 163 | 0.790 |
Why?
| | Middle Aged | 33 | 2022 | 11209 | 0.790 |
Why?
| | Intracellular Signaling Peptides and Proteins | 9 | 2015 | 71 | 0.780 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 4 | 2014 | 48 | 0.770 |
Why?
| | Iodide Peroxidase | 1 | 2021 | 149 | 0.770 |
Why?
| | Endoplasmic Reticulum | 4 | 2017 | 43 | 0.760 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2019 | 3 | 0.760 |
Why?
| | Pseudomonas aeruginosa | 4 | 2022 | 85 | 0.760 |
Why?
| | rhoA GTP-Binding Protein | 4 | 2020 | 11 | 0.750 |
Why?
| | Cardiac Surgical Procedures | 1 | 2020 | 98 | 0.730 |
Why?
| | Gene Expression | 9 | 2011 | 272 | 0.730 |
Why?
| | Disease Models, Animal | 10 | 2020 | 832 | 0.700 |
Why?
| | Nerve Tissue Proteins | 4 | 2015 | 187 | 0.700 |
Why?
| | Calcium | 7 | 2019 | 519 | 0.690 |
Why?
| | Cell Differentiation | 11 | 2018 | 174 | 0.690 |
Why?
| | Adult | 31 | 2021 | 9779 | 0.690 |
Why?
| | Endoplasmic Reticulum-Associated Degradation | 1 | 2017 | 4 | 0.690 |
Why?
| | Apoptosis | 11 | 2017 | 292 | 0.690 |
Why?
| | Diabetes Mellitus, Experimental | 5 | 2022 | 35 | 0.670 |
Why?
| | Zebrafish | 8 | 2017 | 28 | 0.660 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2018 | 224 | 0.660 |
Why?
| | Gene Expression Regulation | 12 | 2017 | 351 | 0.650 |
Why?
| | Genetic Predisposition to Disease | 5 | 2017 | 462 | 0.650 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 4 | 2021 | 31 | 0.640 |
Why?
| | Adolescent | 19 | 2021 | 2667 | 0.640 |
Why?
| | Myeloid Cells | 1 | 2016 | 19 | 0.630 |
Why?
| | Plasmapheresis | 3 | 2013 | 17 | 0.630 |
Why?
| | Genetic Vectors | 3 | 2015 | 71 | 0.630 |
Why?
| | Proportional Hazards Models | 7 | 2021 | 390 | 0.630 |
Why?
| | Lentivirus | 2 | 2015 | 12 | 0.620 |
Why?
| | Renin | 2 | 2015 | 4 | 0.610 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2017 | 227 | 0.590 |
Why?
| | Calcium Channels | 2 | 2008 | 137 | 0.580 |
Why?
| | Longevity | 1 | 2015 | 35 | 0.580 |
Why?
| | Cell Lineage | 1 | 2015 | 34 | 0.580 |
Why?
| | Measles virus | 1 | 2015 | 2 | 0.570 |
Why?
| | Chromatography, Ion Exchange | 1 | 2015 | 16 | 0.560 |
Why?
| | Rats | 18 | 2018 | 966 | 0.560 |
Why?
| | Renal Insufficiency | 4 | 2022 | 22 | 0.560 |
Why?
| | Mutation | 10 | 2011 | 464 | 0.550 |
Why?
| | Immunologic Factors | 5 | 2022 | 53 | 0.550 |
Why?
| | Recurrence | 12 | 2019 | 389 | 0.550 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2017 | 68 | 0.550 |
Why?
| | Plasma Exchange | 4 | 2019 | 20 | 0.550 |
Why?
| | Transcription Factors | 3 | 2015 | 180 | 0.540 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2014 | 12 | 0.520 |
Why?
| | HEK293 Cells | 8 | 2020 | 89 | 0.520 |
Why?
| | Complement System Proteins | 1 | 2013 | 15 | 0.520 |
Why?
| | Immunity, Cellular | 1 | 2013 | 68 | 0.510 |
Why?
| | Cell Line | 12 | 2019 | 360 | 0.500 |
Why?
| | Microscopy, Electron | 7 | 2019 | 100 | 0.500 |
Why?
| | Escherichia coli | 4 | 2006 | 66 | 0.500 |
Why?
| | Immunosorbent Techniques | 1 | 2013 | 6 | 0.500 |
Why?
| | Zebrafish Proteins | 3 | 2011 | 10 | 0.490 |
Why?
| | Hospital Mortality | 4 | 2022 | 192 | 0.490 |
Why?
| | rho GTP-Binding Proteins | 2 | 2014 | 10 | 0.490 |
Why?
| | Protein C | 3 | 2020 | 13 | 0.490 |
Why?
| | Placental Circulation | 1 | 2012 | 2 | 0.490 |
Why?
| | Aged | 20 | 2021 | 10295 | 0.490 |
Why?
| | African Americans | 5 | 2021 | 818 | 0.470 |
Why?
| | Young Adult | 14 | 2021 | 2277 | 0.470 |
Why?
| | Actin Cytoskeleton | 8 | 2022 | 21 | 0.470 |
Why?
| | Coronary Artery Disease | 3 | 2020 | 159 | 0.460 |
Why?
| | Puromycin Aminonucleoside | 5 | 2021 | 13 | 0.460 |
Why?
| | Cations, Divalent | 1 | 2011 | 12 | 0.450 |
Why?
| | Biopsy | 6 | 2019 | 283 | 0.450 |
Why?
| | Pronephros | 1 | 2011 | 2 | 0.450 |
Why?
| | Amino Acid Transport Systems, Basic | 1 | 2011 | 3 | 0.450 |
Why?
| | Receptors, Glucocorticoid | 1 | 2011 | 8 | 0.450 |
Why?
| | Puumala virus | 3 | 2020 | 3 | 0.440 |
Why?
| | Pseudomonas Infections | 2 | 2022 | 63 | 0.440 |
Why?
| | Child | 14 | 2019 | 1572 | 0.430 |
Why?
| | Paracrine Communication | 1 | 2011 | 8 | 0.430 |
Why?
| | Models, Biological | 7 | 2017 | 428 | 0.430 |
Why?
| | Disease Progression | 7 | 2020 | 861 | 0.430 |
Why?
| | Angiopoietins | 1 | 2011 | 16 | 0.420 |
Why?
| | Hypertension | 2 | 2017 | 283 | 0.410 |
Why?
| | Critical Illness | 3 | 2021 | 125 | 0.410 |
Why?
| | Kidney Tubules | 4 | 2021 | 15 | 0.410 |
Why?
| | Inflammation | 6 | 2022 | 360 | 0.410 |
Why?
| | Up-Regulation | 6 | 2017 | 220 | 0.410 |
Why?
| | Kaplan-Meier Estimate | 5 | 2019 | 230 | 0.410 |
Why?
| | Cysteine Endopeptidases | 2 | 2007 | 17 | 0.400 |
Why?
| | Receptors, Cell Surface | 2 | 2007 | 57 | 0.400 |
Why?
| | Risk Factors | 10 | 2021 | 2664 | 0.390 |
Why?
| | Prospective Studies | 11 | 2021 | 1934 | 0.390 |
Why?
| | Respiratory Insufficiency | 2 | 2021 | 48 | 0.390 |
Why?
| | Cell Movement | 5 | 2018 | 119 | 0.380 |
Why?
| | Time Factors | 8 | 2019 | 1902 | 0.380 |
Why?
| | Integrins | 4 | 2017 | 27 | 0.380 |
Why?
| | Intensive Care Units | 3 | 2021 | 316 | 0.370 |
Why?
| | Lipopolysaccharides | 5 | 2017 | 138 | 0.370 |
Why?
| | Aging | 2 | 2018 | 1614 | 0.360 |
Why?
| | Phosphoproteins | 3 | 2014 | 36 | 0.360 |
Why?
| | Gene Expression Regulation, Enzymologic | 3 | 2014 | 40 | 0.360 |
Why?
| | Mice, SCID | 4 | 2016 | 64 | 0.360 |
Why?
| | Microscopy, Fluorescence | 5 | 2017 | 112 | 0.360 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 102 | 0.350 |
Why?
| | Hyperglycemia | 2 | 2022 | 49 | 0.350 |
Why?
| | Coronavirus Infections | 2 | 2020 | 97 | 0.340 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2007 | 5 | 0.340 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 9 | 0.340 |
Why?
| | Integrin alpha3 | 2 | 2004 | 4 | 0.340 |
Why?
| | Risk Assessment | 5 | 2020 | 806 | 0.340 |
Why?
| | Proto-Oncogene Proteins c-kit | 3 | 2018 | 23 | 0.330 |
Why?
| | Indoles | 2 | 2017 | 58 | 0.330 |
Why?
| | Macrophages | 4 | 2021 | 129 | 0.320 |
Why?
| | Mice, Inbred BALB C | 6 | 2019 | 296 | 0.320 |
Why?
| | Molecular Sequence Data | 10 | 2011 | 315 | 0.320 |
Why?
| | Pyelonephritis | 1 | 2006 | 2 | 0.320 |
Why?
| | Emphysema | 1 | 2006 | 3 | 0.320 |
Why?
| | Escherichia coli Infections | 1 | 2006 | 32 | 0.320 |
Why?
| | Glucose | 5 | 2022 | 76 | 0.320 |
Why?
| | Endoplasmic Reticulum Stress | 2 | 2017 | 13 | 0.310 |
Why?
| | Class Ia Phosphatidylinositol 3-Kinase | 2 | 2017 | 6 | 0.310 |
Why?
| | Tight Junctions | 2 | 2011 | 29 | 0.310 |
Why?
| | Treatment Outcome | 8 | 2019 | 3910 | 0.300 |
Why?
| | Anti-Inflammatory Agents | 2 | 2019 | 109 | 0.300 |
Why?
| | Hantavirus | 2 | 2018 | 2 | 0.300 |
Why?
| | Sirolimus | 2 | 2017 | 20 | 0.290 |
Why?
| | Antibodies, Monoclonal | 3 | 2020 | 301 | 0.290 |
Why?
| | Focal Adhesions | 5 | 2016 | 15 | 0.280 |
Why?
| | DNA | 2 | 2021 | 139 | 0.280 |
Why?
| | Peptide Hydrolases | 2 | 2017 | 21 | 0.280 |
Why?
| | Insulin | 3 | 2017 | 116 | 0.270 |
Why?
| | Early Medical Intervention | 2 | 2021 | 18 | 0.270 |
Why?
| | Cell Proliferation | 2 | 2017 | 232 | 0.270 |
Why?
| | Cohort Studies | 7 | 2021 | 2014 | 0.270 |
Why?
| | Recombinant Proteins | 7 | 2015 | 295 | 0.270 |
Why?
| | RNA, Messenger | 6 | 2011 | 371 | 0.260 |
Why?
| | Integrin beta Chains | 2 | 2015 | 3 | 0.260 |
Why?
| | Genes, Fungal | 2 | 1994 | 4 | 0.260 |
Why?
| | Odds Ratio | 3 | 2020 | 327 | 0.260 |
Why?
| | Prednisone | 2 | 2015 | 75 | 0.260 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2022 | 22 | 0.260 |
Why?
| | Chemotaxis, Leukocyte | 2 | 2022 | 21 | 0.260 |
Why?
| | Mortality | 2 | 2021 | 99 | 0.260 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2021 | 9 | 0.250 |
Why?
| | Base Sequence | 9 | 2011 | 166 | 0.250 |
Why?
| | Nuclear Proteins | 2 | 2017 | 97 | 0.250 |
Why?
| | Amino Acid Sequence | 8 | 2010 | 254 | 0.250 |
Why?
| | Child, Preschool | 10 | 2019 | 786 | 0.250 |
Why?
| | Blotting, Western | 6 | 2011 | 225 | 0.250 |
Why?
| | Interleukin-10 | 2 | 2021 | 42 | 0.250 |
Why?
| | Rats, Sprague-Dawley | 9 | 2013 | 494 | 0.240 |
Why?
| | Mast Cells | 3 | 2012 | 45 | 0.240 |
Why?
| | Renal Replacement Therapy | 2 | 2019 | 23 | 0.240 |
Why?
| | Complement C1q | 1 | 2022 | 5 | 0.230 |
Why?
| | Phosphorylation | 7 | 2022 | 199 | 0.230 |
Why?
| | Flow Cytometry | 3 | 2012 | 217 | 0.230 |
Why?
| | Incidence | 4 | 2020 | 829 | 0.230 |
Why?
| | Models, Animal | 3 | 2018 | 149 | 0.230 |
Why?
| | Cicatrix | 1 | 2022 | 13 | 0.230 |
Why?
| | Receptors, Formyl Peptide | 1 | 2022 | 3 | 0.230 |
Why?
| | NFATC Transcription Factors | 2 | 2012 | 18 | 0.230 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 34 | 0.230 |
Why?
| | Wound Infection | 1 | 2022 | 13 | 0.230 |
Why?
| | Prognosis | 6 | 2022 | 1028 | 0.230 |
Why?
| | Cell Membrane | 4 | 2016 | 132 | 0.230 |
Why?
| | Toll-Like Receptors | 2 | 2017 | 34 | 0.230 |
Why?
| | Receptors, Thyrotropin | 1 | 2021 | 6 | 0.230 |
Why?
| | C-Reactive Protein | 3 | 2018 | 134 | 0.220 |
Why?
| | Leptin | 2 | 2012 | 27 | 0.220 |
Why?
| | Cell Adhesion Molecules | 2 | 2014 | 45 | 0.220 |
Why?
| | Virus Replication | 2 | 2018 | 96 | 0.220 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2021 | 8 | 0.220 |
Why?
| | DNA-Binding Proteins | 3 | 2015 | 264 | 0.220 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2021 | 24 | 0.220 |
Why?
| | Retrospective Studies | 7 | 2021 | 3591 | 0.220 |
Why?
| | Glucocorticoids | 2 | 2013 | 77 | 0.220 |
Why?
| | Proteomics | 2 | 2022 | 80 | 0.220 |
Why?
| | Protein Multimerization | 2 | 2019 | 23 | 0.210 |
Why?
| | Eating | 1 | 2021 | 61 | 0.210 |
Why?
| | Hemorrhagic Fever with Renal Syndrome | 1 | 2020 | 1 | 0.210 |
Why?
| | Neutrophils | 1 | 2022 | 133 | 0.210 |
Why?
| | Sequence Homology, Amino Acid | 5 | 2010 | 57 | 0.210 |
Why?
| | Cadherins | 2 | 2002 | 38 | 0.210 |
Why?
| | Transfection | 5 | 2015 | 154 | 0.210 |
Why?
| | Thyroid Hormones | 1 | 2021 | 66 | 0.210 |
Why?
| | Embryo, Nonmammalian | 2 | 2012 | 10 | 0.210 |
Why?
| | Wound Healing | 1 | 2022 | 175 | 0.210 |
Why?
| | High-Throughput Screening Assays | 2 | 2017 | 12 | 0.210 |
Why?
| | Triiodothyronine | 1 | 2021 | 113 | 0.200 |
Why?
| | Leukocyte Transfusion | 1 | 2020 | 3 | 0.200 |
Why?
| | Protein Isoforms | 2 | 2019 | 60 | 0.200 |
Why?
| | Proteolysis | 2 | 2017 | 20 | 0.200 |
Why?
| | Cell Adhesion | 4 | 2014 | 51 | 0.200 |
Why?
| | Melanoma | 1 | 2021 | 63 | 0.200 |
Why?
| | Cloning, Molecular | 6 | 2008 | 47 | 0.200 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2000 | 8 | 0.200 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 106 | 0.200 |
Why?
| | Immunoglobulin G | 4 | 2014 | 134 | 0.200 |
Why?
| | Colorectal Neoplasms | 1 | 2022 | 125 | 0.200 |
Why?
| | Apolipoprotein C-III | 1 | 2019 | 3 | 0.200 |
Why?
| | Caspase 8 | 1 | 2019 | 13 | 0.200 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 1 | 2019 | 15 | 0.200 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2017 | 15 | 0.190 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 136 | 0.190 |
Why?
| | Obesity | 3 | 2012 | 338 | 0.190 |
Why?
| | Sphingomyelin Phosphodiesterase | 3 | 2014 | 12 | 0.190 |
Why?
| | Calmodulin | 1 | 2019 | 12 | 0.190 |
Why?
| | Adipose Tissue | 2 | 2018 | 98 | 0.190 |
Why?
| | Receptor, PAR-2 | 1 | 2019 | 4 | 0.190 |
Why?
| | Tissue Donors | 1 | 2020 | 79 | 0.190 |
Why?
| | Cyclosporine | 2 | 2009 | 19 | 0.190 |
Why?
| | Adipocytes | 1 | 2019 | 23 | 0.190 |
Why?
| | Monocytes | 1 | 2019 | 108 | 0.190 |
Why?
| | Inducible T-Cell Co-Stimulator Ligand | 1 | 2019 | 7 | 0.190 |
Why?
| | Prednisolone | 1 | 2019 | 9 | 0.190 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 148 | 0.190 |
Why?
| | Hantavirus Infections | 1 | 2018 | 1 | 0.190 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2019 | 11 | 0.190 |
Why?
| | Hantaan virus | 1 | 2018 | 1 | 0.190 |
Why?
| | Postoperative Complications | 2 | 2020 | 1083 | 0.180 |
Why?
| | Cell Death | 1 | 2018 | 68 | 0.180 |
Why?
| | Regeneration | 1 | 2018 | 30 | 0.180 |
Why?
| | Calcineurin | 3 | 2013 | 13 | 0.180 |
Why?
| | Genotype | 2 | 2017 | 423 | 0.180 |
Why?
| | Antibodies | 3 | 2014 | 72 | 0.180 |
Why?
| | Nephrons | 1 | 2018 | 9 | 0.180 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 22 | 0.170 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 27 | 0.170 |
Why?
| | Sesquiterpenes, Guaiane | 1 | 2017 | 3 | 0.170 |
Why?
| | Immunohistochemistry | 6 | 2012 | 494 | 0.170 |
Why?
| | Protein Folding | 1 | 2017 | 26 | 0.170 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2013 | 230 | 0.170 |
Why?
| | Renal Agents | 1 | 2017 | 4 | 0.170 |
Why?
| | Benzazepines | 1 | 2017 | 10 | 0.170 |
Why?
| | Mycophenolic Acid | 2 | 2015 | 14 | 0.170 |
Why?
| | Proteome | 1 | 2018 | 31 | 0.170 |
Why?
| | Protective Agents | 1 | 2017 | 11 | 0.170 |
Why?
| | Piperidines | 1 | 2017 | 35 | 0.170 |
Why?
| | DNA, Complementary | 4 | 2008 | 39 | 0.170 |
Why?
| | Bone and Bones | 1 | 2018 | 110 | 0.170 |
Why?
| | Sepsis | 1 | 2019 | 157 | 0.170 |
Why?
| | Doxorubicin | 3 | 2017 | 83 | 0.170 |
Why?
| | Surface Plasmon Resonance | 1 | 2017 | 9 | 0.170 |
Why?
| | Drug Discovery | 1 | 2017 | 24 | 0.170 |
Why?
| | Drosophila Proteins | 1 | 2017 | 13 | 0.170 |
Why?
| | HIV-1 | 2 | 2001 | 446 | 0.170 |
Why?
| | Receptor, PAR-1 | 2 | 2020 | 2 | 0.170 |
Why?
| | Endocytosis | 2 | 2015 | 20 | 0.170 |
Why?
| | Germany | 1 | 2017 | 12 | 0.170 |
Why?
| | Blood Coagulation | 1 | 2017 | 28 | 0.170 |
Why?
| | Cytoprotection | 2 | 2020 | 11 | 0.160 |
Why?
| | PPAR gamma | 1 | 2017 | 16 | 0.160 |
Why?
| | Multiprotein Complexes | 1 | 2017 | 8 | 0.160 |
Why?
| | Defective Viruses | 1 | 1996 | 2 | 0.160 |
Why?
| | Peripheral Arterial Disease | 1 | 2017 | 21 | 0.160 |
Why?
| | Receptor, ErbB-4 | 1 | 2016 | 3 | 0.160 |
Why?
| | Receptor, Notch1 | 1 | 2016 | 10 | 0.160 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 410 | 0.160 |
Why?
| | Alleles | 1 | 2017 | 221 | 0.160 |
Why?
| | Cause of Death | 1 | 2017 | 78 | 0.160 |
Why?
| | Bone Marrow Cells | 1 | 2016 | 63 | 0.160 |
Why?
| | Protein Conformation | 2 | 2014 | 94 | 0.160 |
Why?
| | Adoptive Transfer | 1 | 2016 | 51 | 0.160 |
Why?
| | Culture Media | 2 | 2001 | 44 | 0.160 |
Why?
| | Disease-Free Survival | 1 | 2017 | 241 | 0.160 |
Why?
| | Fingers | 1 | 2016 | 13 | 0.150 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 235 | 0.150 |
Why?
| | Predictive Value of Tests | 4 | 2021 | 637 | 0.150 |
Why?
| | Vasculitis | 1 | 2016 | 35 | 0.150 |
Why?
| | Cell Survival | 3 | 2013 | 181 | 0.150 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2016 | 42 | 0.150 |
Why?
| | Aged, 80 and over | 4 | 2020 | 5234 | 0.150 |
Why?
| | Permeability | 2 | 2014 | 143 | 0.150 |
Why?
| | Calcineurin Inhibitors | 2 | 2013 | 11 | 0.150 |
Why?
| | Interferon-alpha | 1 | 2016 | 71 | 0.150 |
Why?
| | Polymerase Chain Reaction | 4 | 2011 | 188 | 0.150 |
Why?
| | Galactose | 1 | 2015 | 6 | 0.150 |
Why?
| | Receptors, Purinergic P2X4 | 1 | 2015 | 1 | 0.150 |
Why?
| | Mechanotransduction, Cellular | 1 | 2015 | 6 | 0.150 |
Why?
| | Case-Control Studies | 4 | 2020 | 687 | 0.150 |
Why?
| | Cyanoacrylates | 1 | 2015 | 1 | 0.140 |
Why?
| | Coumaric Acids | 1 | 2015 | 2 | 0.140 |
Why?
| | Adenosine Triphosphate | 1 | 2015 | 46 | 0.140 |
Why?
| | Basement Membrane | 2 | 2008 | 16 | 0.140 |
Why?
| | Hydroxyquinolines | 1 | 2015 | 5 | 0.140 |
Why?
| | Activating Transcription Factor 6 | 1 | 2015 | 1 | 0.140 |
Why?
| | CHO Cells | 1 | 1995 | 24 | 0.140 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2015 | 6 | 0.140 |
Why?
| | Cyclosporins | 1 | 2015 | 4 | 0.140 |
Why?
| | Microtubules | 3 | 2017 | 32 | 0.140 |
Why?
| | Molecular Imaging | 1 | 2015 | 7 | 0.140 |
Why?
| | Bacterial Proteins | 2 | 1994 | 90 | 0.140 |
Why?
| | Agaricales | 1 | 1994 | 1 | 0.140 |
Why?
| | Alcohol Oxidoreductases | 1 | 1994 | 2 | 0.140 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 100 | 0.140 |
Why?
| | CTLA-4 Antigen | 1 | 2014 | 6 | 0.140 |
Why?
| | Immunoprecipitation | 2 | 2011 | 26 | 0.140 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2014 | 1 | 0.140 |
Why?
| | Sulfonamides | 1 | 2015 | 64 | 0.140 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2014 | 3 | 0.140 |
Why?
| | Linear Models | 1 | 2015 | 276 | 0.140 |
Why?
| | Apolipoprotein A-I | 1 | 2014 | 6 | 0.140 |
Why?
| | Glycoproteins | 1 | 2015 | 65 | 0.140 |
Why?
| | Peritoneal Dialysis | 2 | 2012 | 27 | 0.140 |
Why?
| | Point Mutation | 2 | 2013 | 37 | 0.140 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2014 | 1 | 0.140 |
Why?
| | Adiposity | 2 | 2012 | 51 | 0.140 |
Why?
| | Dexamethasone | 1 | 2015 | 52 | 0.140 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2015 | 43 | 0.140 |
Why?
| | Biological Transport, Active | 1 | 2014 | 21 | 0.130 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 111 | 0.130 |
Why?
| | Glycolipids | 1 | 1994 | 4 | 0.130 |
Why?
| | Genes, Regulator | 1 | 1994 | 4 | 0.130 |
Why?
| | Subcutaneous Fat | 2 | 2012 | 14 | 0.130 |
Why?
| | Genes, Bacterial | 1 | 1994 | 8 | 0.130 |
Why?
| | Surface-Active Agents | 1 | 1994 | 7 | 0.130 |
Why?
| | Talin | 1 | 2014 | 3 | 0.130 |
Why?
| | Cell Membrane Permeability | 1 | 2014 | 63 | 0.130 |
Why?
| | Cell Culture Techniques | 2 | 2020 | 52 | 0.130 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2017 | 193 | 0.130 |
Why?
| | Anterior Eye Segment | 1 | 2014 | 2 | 0.130 |
Why?
| | Pandemics | 3 | 2020 | 203 | 0.130 |
Why?
| | rac1 GTP-Binding Protein | 2 | 2014 | 14 | 0.130 |
Why?
| | Hospitalization | 3 | 2022 | 359 | 0.130 |
Why?
| | Glomerulonephritis, Membranous | 1 | 2013 | 8 | 0.130 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2014 | 177 | 0.130 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 33 | 0.130 |
Why?
| | Autoantibodies | 1 | 2014 | 119 | 0.130 |
Why?
| | Embryonic Stem Cells | 1 | 2013 | 15 | 0.130 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2013 | 43 | 0.130 |
Why?
| | Enzyme Activation | 1 | 2013 | 140 | 0.120 |
Why?
| | Pancreatitis | 2 | 2010 | 29 | 0.120 |
Why?
| | Urothelium | 2 | 2004 | 9 | 0.120 |
Why?
| | Mixed Function Oxygenases | 1 | 1992 | 6 | 0.120 |
Why?
| | Trichosporon | 1 | 1992 | 3 | 0.120 |
Why?
| | Infant, Newborn | 2 | 2012 | 754 | 0.120 |
Why?
| | Fibroblast Growth Factors | 1 | 2012 | 9 | 0.120 |
Why?
| | Glucuronidase | 1 | 2012 | 14 | 0.120 |
Why?
| | Diagnosis, Differential | 2 | 2013 | 467 | 0.120 |
Why?
| | Nephrology | 1 | 2012 | 16 | 0.120 |
Why?
| | Actinin | 2 | 2018 | 9 | 0.120 |
Why?
| | Cytokines | 1 | 2014 | 364 | 0.120 |
Why?
| | HeLa Cells | 5 | 2021 | 58 | 0.110 |
Why?
| | Abdominal Fat | 1 | 2012 | 12 | 0.110 |
Why?
| | Receptors, Immunologic | 1 | 2012 | 35 | 0.110 |
Why?
| | Toll-Like Receptor 4 | 2 | 2019 | 32 | 0.110 |
Why?
| | Kidney Function Tests | 3 | 2019 | 29 | 0.110 |
Why?
| | Receptors, Thrombin | 1 | 2011 | 2 | 0.110 |
Why?
| | Membrane Microdomains | 2 | 2011 | 18 | 0.110 |
Why?
| | HIV Infections | 1 | 2019 | 951 | 0.110 |
Why?
| | Adiponectin | 1 | 2011 | 13 | 0.110 |
Why?
| | Exotoxins | 2 | 2022 | 16 | 0.110 |
Why?
| | Vaccines, DNA | 1 | 2011 | 10 | 0.110 |
Why?
| | Small Molecule Libraries | 1 | 2011 | 5 | 0.110 |
Why?
| | Angiotensin II | 1 | 2011 | 9 | 0.110 |
Why?
| | Macrophage-1 Antigen | 1 | 2011 | 11 | 0.110 |
Why?
| | ADP Ribose Transferases | 2 | 2022 | 17 | 0.110 |
Why?
| | Feedback, Physiological | 1 | 2011 | 20 | 0.110 |
Why?
| | Biomedical Research | 1 | 2012 | 89 | 0.110 |
Why?
| | Follow-Up Studies | 4 | 2020 | 2028 | 0.110 |
Why?
| | Leukocytes | 1 | 2011 | 50 | 0.110 |
Why?
| | Lymph Nodes | 1 | 2012 | 84 | 0.110 |
Why?
| | Ubiquinone | 1 | 2011 | 5 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2015 | 1240 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2011 | 10 | 0.110 |
Why?
| | Calcium Signaling | 1 | 2013 | 188 | 0.110 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2011 | 17 | 0.110 |
Why?
| | Glomerular Basement Membrane | 1 | 2011 | 2 | 0.110 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2011 | 13 | 0.110 |
Why?
| | Pregnancy | 1 | 2012 | 457 | 0.110 |
Why?
| | Exons | 1 | 2011 | 46 | 0.110 |
Why?
| | Inflammasomes | 2 | 2022 | 18 | 0.110 |
Why?
| | Endothelial Cells | 1 | 2011 | 67 | 0.110 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2010 | 2 | 0.110 |
Why?
| | Genome, Mitochondrial | 1 | 2010 | 2 | 0.110 |
Why?
| | Gelsolin | 1 | 2010 | 1 | 0.110 |
Why?
| | Stress Fibers | 1 | 2010 | 2 | 0.110 |
Why?
| | Cathepsin B | 1 | 2010 | 6 | 0.100 |
Why?
| | Ventricular Remodeling | 1 | 2010 | 10 | 0.100 |
Why?
| | Capillaries | 2 | 2008 | 15 | 0.100 |
Why?
| | Potassium Channels, Calcium-Activated | 1 | 2010 | 2 | 0.100 |
Why?
| | NIH 3T3 Cells | 1 | 2010 | 6 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2013 | 389 | 0.100 |
Why?
| | Protein Transport | 1 | 2010 | 42 | 0.100 |
Why?
| | beta-Galactosidase | 1 | 2010 | 9 | 0.100 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2010 | 26 | 0.100 |
Why?
| | Immunoglobulins | 1 | 2010 | 35 | 0.100 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 48 | 0.100 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2010 | 36 | 0.100 |
Why?
| | Physiological Phenomena | 1 | 2010 | 1 | 0.100 |
Why?
| | Dosage Forms | 1 | 2010 | 2 | 0.100 |
Why?
| | Genetic Techniques | 1 | 2010 | 4 | 0.100 |
Why?
| | ROC Curve | 1 | 2010 | 153 | 0.100 |
Why?
| | Liver | 3 | 2022 | 214 | 0.100 |
Why?
| | cdc42 GTP-Binding Protein | 1 | 2009 | 5 | 0.100 |
Why?
| | Pedigree | 2 | 2011 | 72 | 0.100 |
Why?
| | Islets of Langerhans | 1 | 2009 | 4 | 0.100 |
Why?
| | Pharmaceutical Preparations | 1 | 2010 | 24 | 0.100 |
Why?
| | Cell Communication | 3 | 2011 | 36 | 0.100 |
Why?
| | Cytosol | 1 | 2009 | 61 | 0.100 |
Why?
| | Immunoblotting | 2 | 2012 | 65 | 0.100 |
Why?
| | Acute Disease | 1 | 2010 | 254 | 0.100 |
Why?
| | Genome-Wide Association Study | 1 | 2011 | 315 | 0.100 |
Why?
| | COS Cells | 3 | 2011 | 51 | 0.090 |
Why?
| | Myocardium | 1 | 2010 | 183 | 0.090 |
Why?
| | Brain | 2 | 2017 | 1655 | 0.090 |
Why?
| | Caenorhabditis elegans | 1 | 2008 | 8 | 0.090 |
Why?
| | Down-Regulation | 2 | 2011 | 134 | 0.090 |
Why?
| | United States | 3 | 2021 | 2539 | 0.090 |
Why?
| | Age Factors | 3 | 2020 | 943 | 0.090 |
Why?
| | Cell Cycle Proteins | 1 | 2008 | 15 | 0.090 |
Why?
| | Gene Expression Profiling | 2 | 2011 | 183 | 0.090 |
Why?
| | Conserved Sequence | 1 | 2008 | 10 | 0.090 |
Why?
| | Muscle, Smooth | 1 | 2008 | 15 | 0.090 |
Why?
| | In Situ Hybridization | 1 | 2008 | 63 | 0.090 |
Why?
| | Protein Kinase C | 1 | 2008 | 55 | 0.090 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 82 | 0.090 |
Why?
| | Phylogeny | 1 | 2008 | 67 | 0.090 |
Why?
| | Interleukin-6 | 3 | 2013 | 120 | 0.090 |
Why?
| | Gene Transfer Techniques | 1 | 2007 | 36 | 0.080 |
Why?
| | Epididymis | 3 | 2012 | 12 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 100 | 0.080 |
Why?
| | DNA Mutational Analysis | 3 | 2013 | 73 | 0.080 |
Why?
| | Random Allocation | 3 | 2015 | 164 | 0.080 |
Why?
| | Organ Specificity | 3 | 2012 | 58 | 0.080 |
Why?
| | WT1 Proteins | 3 | 2018 | 5 | 0.080 |
Why?
| | Fatal Outcome | 1 | 2006 | 75 | 0.080 |
Why?
| | Zonula Occludens-1 Protein | 2 | 2011 | 18 | 0.080 |
Why?
| | Cholesterol | 3 | 2015 | 68 | 0.080 |
Why?
| | Fluorescent Antibody Technique | 2 | 2011 | 84 | 0.080 |
Why?
| | Blood Pressure | 1 | 2007 | 260 | 0.080 |
Why?
| | Remission Induction | 2 | 2019 | 119 | 0.080 |
Why?
| | Prevalence | 2 | 2019 | 544 | 0.080 |
Why?
| | Survival Rate | 2 | 2020 | 465 | 0.080 |
Why?
| | RNA, Small Interfering | 3 | 2010 | 72 | 0.070 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2005 | 4 | 0.070 |
Why?
| | Microscopy, Immunoelectron | 1 | 2005 | 6 | 0.070 |
Why?
| | Diet | 2 | 2021 | 202 | 0.070 |
Why?
| | Ultrasonography | 1 | 2006 | 210 | 0.070 |
Why?
| | Anticoagulants | 2 | 2021 | 151 | 0.070 |
Why?
| | Cell Polarity | 2 | 2008 | 10 | 0.070 |
Why?
| | Puromycin | 1 | 2004 | 2 | 0.070 |
Why?
| | Blotting, Northern | 1 | 2004 | 29 | 0.070 |
Why?
| | Cell Cycle | 3 | 2002 | 43 | 0.070 |
Why?
| | Chemokine CCL2 | 2 | 2016 | 25 | 0.070 |
Why?
| | Microscopy, Confocal | 2 | 2015 | 128 | 0.070 |
Why?
| | Restriction Mapping | 2 | 1994 | 7 | 0.070 |
Why?
| | Molecular Weight | 2 | 2013 | 58 | 0.070 |
Why?
| | Extracellular Matrix | 1 | 2004 | 92 | 0.070 |
Why?
| | Plasmids | 2 | 1995 | 52 | 0.060 |
Why?
| | Tyrosine | 2 | 2001 | 28 | 0.060 |
Why?
| | In Vitro Techniques | 1 | 2004 | 248 | 0.060 |
Why?
| | Cell Division | 3 | 2001 | 122 | 0.060 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 111 | 0.060 |
Why?
| | Peptide Fragments | 2 | 1994 | 122 | 0.060 |
Why?
| | RNA Interference | 2 | 2015 | 42 | 0.060 |
Why?
| | Antigens, CD20 | 2 | 2013 | 8 | 0.060 |
Why?
| | DNA Primers | 2 | 2009 | 64 | 0.060 |
Why?
| | NF-kappa B | 2 | 2013 | 112 | 0.060 |
Why?
| | Microsatellite Instability | 1 | 2022 | 9 | 0.060 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 16 | 0.060 |
Why?
| | Tropism | 1 | 2022 | 1 | 0.060 |
Why?
| | Cystatin C | 1 | 2022 | 4 | 0.060 |
Why?
| | Chemokine CCL3 | 1 | 2022 | 14 | 0.060 |
Why?
| | GTPase-Activating Proteins | 1 | 2022 | 9 | 0.060 |
Why?
| | Interleukin-8 | 1 | 2022 | 38 | 0.060 |
Why?
| | Drug Evaluation | 1 | 2022 | 58 | 0.060 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2022 | 40 | 0.060 |
Why?
| | Chemokines | 1 | 2021 | 31 | 0.060 |
Why?
| | Transcriptome | 1 | 2022 | 87 | 0.050 |
Why?
| | Cytological Techniques | 2 | 2002 | 18 | 0.050 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2021 | 5 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2006 | 891 | 0.050 |
Why?
| | Diabetes Complications | 1 | 2022 | 74 | 0.050 |
Why?
| | RNA, Viral | 1 | 2021 | 163 | 0.050 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2001 | 8 | 0.050 |
Why?
| | Aspartate Aminotransferases | 1 | 2021 | 20 | 0.050 |
Why?
| | Receptors, Interleukin-6 | 1 | 2021 | 7 | 0.050 |
Why?
| | Primary Prevention | 1 | 2021 | 53 | 0.050 |
Why?
| | Serpins | 1 | 2001 | 5 | 0.050 |
Why?
| | Interleukin-12 | 1 | 2021 | 41 | 0.050 |
Why?
| | Eye Proteins | 1 | 2001 | 9 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2021 | 79 | 0.050 |
Why?
| | Organ Dysfunction Scores | 1 | 2021 | 8 | 0.050 |
Why?
| | Prone Position | 1 | 2021 | 25 | 0.050 |
Why?
| | Cerebellum | 1 | 2001 | 57 | 0.050 |
Why?
| | Patient Positioning | 1 | 2021 | 35 | 0.050 |
Why?
| | GTP-Binding Protein alpha Subunits, G12-G13 | 1 | 2020 | 3 | 0.050 |
Why?
| | Vanadates | 1 | 2000 | 4 | 0.050 |
Why?
| | Protamines | 1 | 2000 | 6 | 0.050 |
Why?
| | Nerve Growth Factors | 1 | 2001 | 46 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2020 | 54 | 0.050 |
Why?
| | Microscopy, Electron, Scanning Transmission | 1 | 2000 | 1 | 0.050 |
Why?
| | Tissue Inhibitor of Metalloproteinase-2 | 1 | 2019 | 2 | 0.050 |
Why?
| | Drug Resistance | 2 | 2015 | 68 | 0.050 |
Why?
| | China | 1 | 2020 | 66 | 0.050 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 23 | 0.050 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 38 | 0.050 |
Why?
| | Respiration, Artificial | 1 | 2021 | 116 | 0.050 |
Why?
| | rab GTP-Binding Proteins | 1 | 1999 | 2 | 0.050 |
Why?
| | Vesicular stomatitis Indiana virus | 1 | 1999 | 6 | 0.050 |
Why?
| | Toll-Like Receptor 2 | 1 | 2019 | 36 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 191 | 0.050 |
Why?
| | Viral Proteins | 1 | 1999 | 30 | 0.050 |
Why?
| | Stress, Mechanical | 2 | 2015 | 198 | 0.050 |
Why?
| | Binding Sites | 1 | 2019 | 93 | 0.050 |
Why?
| | Cricetinae | 2 | 1998 | 52 | 0.050 |
Why?
| | Amino Acid Motifs | 1 | 2019 | 20 | 0.050 |
Why?
| | Molecular Motor Proteins | 1 | 1998 | 2 | 0.050 |
Why?
| | Gels | 1 | 2019 | 11 | 0.050 |
Why?
| | Baltimore | 1 | 2019 | 16 | 0.050 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 133 | 0.050 |
Why?
| | Nucleocapsid Proteins | 1 | 2018 | 2 | 0.050 |
Why?
| | Vero Cells | 1 | 2018 | 8 | 0.050 |
Why?
| | Viral Core Proteins | 1 | 2018 | 6 | 0.050 |
Why?
| | Microtubule-Associated Proteins | 1 | 1998 | 24 | 0.050 |
Why?
| | Virus Release | 1 | 2018 | 3 | 0.050 |
Why?
| | Missouri | 1 | 2019 | 27 | 0.050 |
Why?
| | Lymphocyte Subsets | 1 | 2019 | 31 | 0.050 |
Why?
| | Reperfusion Injury | 1 | 2018 | 9 | 0.050 |
Why?
| | Viral Load | 1 | 2019 | 213 | 0.050 |
Why?
| | Allografts | 1 | 2020 | 171 | 0.050 |
Why?
| | Capsid Proteins | 1 | 2018 | 29 | 0.050 |
Why?
| | Patient Outcome Assessment | 1 | 2019 | 50 | 0.040 |
Why?
| | Bone Development | 1 | 2018 | 34 | 0.040 |
Why?
| | Lysosome-Associated Membrane Glycoproteins | 1 | 2018 | 4 | 0.040 |
Why?
| | Stem Cells | 1 | 2018 | 52 | 0.040 |
Why?
| | Chronic Disease | 1 | 2020 | 544 | 0.040 |
Why?
| | Infant | 2 | 2011 | 642 | 0.040 |
Why?
| | Serum Albumin | 1 | 2018 | 28 | 0.040 |
Why?
| | Sex Factors | 1 | 2020 | 542 | 0.040 |
Why?
| | Telencephalon | 1 | 1997 | 3 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2018 | 44 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2017 | 38 | 0.040 |
Why?
| | Dendrites | 1 | 1997 | 16 | 0.040 |
Why?
| | Animals, Newborn | 2 | 2013 | 77 | 0.040 |
Why?
| | Muscle, Skeletal | 2 | 2012 | 385 | 0.040 |
Why?
| | Thrombomodulin | 1 | 2017 | 4 | 0.040 |
Why?
| | Unfolded Protein Response | 1 | 2017 | 7 | 0.040 |
Why?
| | Georgia | 1 | 2017 | 16 | 0.040 |
Why?
| | Drosophila melanogaster | 1 | 2017 | 21 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2017 | 19 | 0.040 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2017 | 3 | 0.040 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2017 | 3 | 0.040 |
Why?
| | Interferon Regulatory Factor-7 | 1 | 2017 | 4 | 0.040 |
Why?
| | Genes, nef | 1 | 1996 | 1 | 0.040 |
Why?
| | Genes, vpr | 1 | 1996 | 1 | 0.040 |
Why?
| | Genes, vpu | 1 | 1996 | 1 | 0.040 |
Why?
| | Kanamycin Kinase | 1 | 1996 | 1 | 0.040 |
Why?
| | HIV Envelope Protein gp160 | 1 | 1996 | 3 | 0.040 |
Why?
| | Interferon Type I | 1 | 2017 | 20 | 0.040 |
Why?
| | Moloney murine leukemia virus | 1 | 1996 | 3 | 0.040 |
Why?
| | Body Mass Index | 1 | 2020 | 458 | 0.040 |
Why?
| | Ribonucleases | 1 | 2016 | 10 | 0.040 |
Why?
| | Extracellular Matrix Proteins | 1 | 2018 | 176 | 0.040 |
Why?
| | Antigens, CD34 | 1 | 1996 | 19 | 0.040 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 15 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 178 | 0.040 |
Why?
| | Cell Line, Transformed | 3 | 2002 | 21 | 0.040 |
Why?
| | Lymphocytes | 1 | 1996 | 113 | 0.040 |
Why?
| | Skin | 1 | 1996 | 136 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2017 | 390 | 0.040 |
Why?
| | Genetic Therapy | 1 | 1996 | 93 | 0.040 |
Why?
| | Purinergic P2X Receptor Antagonists | 1 | 2015 | 1 | 0.040 |
Why?
| | Benzodiazepinones | 1 | 2015 | 3 | 0.040 |
Why?
| | Logistic Models | 1 | 2017 | 479 | 0.040 |
Why?
| | Acrylamide | 1 | 2015 | 1 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 332 | 0.040 |
Why?
| | Tryptophan Synthase | 1 | 1995 | 1 | 0.040 |
Why?
| | Culture Media, Serum-Free | 1 | 1995 | 8 | 0.040 |
Why?
| | Receptor, Insulin | 1 | 2015 | 3 | 0.040 |
Why?
| | Transcription Factor CHOP | 1 | 2015 | 2 | 0.040 |
Why?
| | Streptozocin | 1 | 2015 | 7 | 0.040 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 1995 | 6 | 0.040 |
Why?
| | Hepatitis C | 1 | 2016 | 68 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2015 | 4 | 0.040 |
Why?
| | Polymerization | 1 | 2015 | 1 | 0.040 |
Why?
| | Time-Lapse Imaging | 1 | 2015 | 10 | 0.040 |
Why?
| | Larva | 1 | 2015 | 3 | 0.040 |
Why?
| | Lim Kinases | 1 | 2015 | 2 | 0.040 |
Why?
| | Actin Depolymerizing Factors | 1 | 2015 | 3 | 0.040 |
Why?
| | Receptor, trkB | 1 | 2015 | 4 | 0.040 |
Why?
| | Cytokinesis | 1 | 2015 | 5 | 0.040 |
Why?
| | Genetic Markers | 1 | 1995 | 51 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2015 | 19 | 0.040 |
Why?
| | Chromatography, Affinity | 1 | 1994 | 11 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2018 | 886 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 47 | 0.030 |
Why?
| | Heparin | 1 | 2015 | 37 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 1994 | 21 | 0.030 |
Why?
| | Genetic Complementation Test | 1 | 1994 | 1 | 0.030 |
Why?
| | Pyocyanine | 1 | 1994 | 1 | 0.030 |
Why?
| | Neuropeptides | 1 | 2014 | 26 | 0.030 |
Why?
| | Alkanes | 1 | 1994 | 4 | 0.030 |
Why?
| | Pancreatic Elastase | 1 | 1994 | 5 | 0.030 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 1994 | 9 | 0.030 |
Why?
| | Calpain | 1 | 2014 | 6 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2014 | 74 | 0.030 |
Why?
| | Histone Deacetylases | 1 | 2014 | 12 | 0.030 |
Why?
| | Acetylation | 1 | 2014 | 15 | 0.030 |
Why?
| | Microinjections | 1 | 2014 | 7 | 0.030 |
Why?
| | Green Fluorescent Proteins | 1 | 2014 | 37 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 4 | 0.030 |
Why?
| | Thrombosis | 1 | 2015 | 67 | 0.030 |
Why?
| | Histones | 1 | 2014 | 32 | 0.030 |
Why?
| | Synaptophysin | 1 | 2013 | 10 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 1994 | 81 | 0.030 |
Why?
| | Kidney Cortex | 1 | 2013 | 1 | 0.030 |
Why?
| | src-Family Kinases | 1 | 2013 | 9 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2013 | 19 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 89 | 0.030 |
Why?
| | Congenital Hypothyroidism | 1 | 2013 | 3 | 0.030 |
Why?
| | Cerebral Palsy | 1 | 2013 | 10 | 0.030 |
Why?
| | Oligonucleotide Probes | 1 | 1992 | 6 | 0.030 |
Why?
| | DNA, Fungal | 1 | 1992 | 4 | 0.030 |
Why?
| | Blotting, Southern | 1 | 1992 | 6 | 0.030 |
Why?
| | Gene Library | 1 | 1992 | 10 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2013 | 29 | 0.030 |
Why?
| | Systems Biology | 1 | 2012 | 10 | 0.030 |
Why?
| | Administration, Oral | 1 | 2013 | 164 | 0.030 |
Why?
| | Substrate Specificity | 1 | 1992 | 38 | 0.030 |
Why?
| | Databases, Factual | 1 | 2015 | 391 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2013 | 87 | 0.030 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2012 | 27 | 0.030 |
Why?
| | Embryonic Development | 1 | 2012 | 8 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 257 | 0.030 |
Why?
| | Genomics | 1 | 2012 | 46 | 0.030 |
Why?
| | Nephrectomy | 1 | 2012 | 44 | 0.030 |
Why?
| | Mice, Obese | 1 | 2012 | 8 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2012 | 76 | 0.030 |
Why?
| | Age of Onset | 1 | 2012 | 113 | 0.030 |
Why?
| | Thymus Gland | 1 | 2012 | 28 | 0.030 |
Why?
| | Spleen | 1 | 2012 | 54 | 0.030 |
Why?
| | Tryptases | 1 | 2011 | 10 | 0.030 |
Why?
| | Thrombin | 1 | 2011 | 14 | 0.030 |
Why?
| | CARD Signaling Adaptor Proteins | 1 | 2011 | 1 | 0.030 |
Why?
| | Immune Sera | 1 | 2011 | 10 | 0.030 |
Why?
| | Ovalbumin | 1 | 2011 | 10 | 0.030 |
Why?
| | Graft Survival | 1 | 2012 | 111 | 0.030 |
Why?
| | Electroporation | 1 | 2011 | 3 | 0.030 |
Why?
| | Mastocytosis | 1 | 2011 | 12 | 0.030 |
Why?
| | Manganese | 1 | 2011 | 4 | 0.030 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2011 | 8 | 0.030 |
Why?
| | K562 Cells | 1 | 2011 | 7 | 0.030 |
Why?
| | Cell Count | 1 | 2012 | 115 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2011 | 27 | 0.030 |
Why?
| | Rabbits | 2 | 2010 | 326 | 0.030 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2011 | 27 | 0.030 |
Why?
| | Organ Size | 1 | 2011 | 122 | 0.030 |
Why?
| | Magnesium | 1 | 2011 | 52 | 0.030 |
Why?
| | Laminin | 1 | 2011 | 10 | 0.030 |
Why?
| | Hybridization, Genetic | 1 | 2011 | 4 | 0.030 |
Why?
| | Homozygote | 1 | 2011 | 28 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2011 | 47 | 0.030 |
Why?
| | Thinness | 1 | 2010 | 6 | 0.030 |
Why?
| | Quality Control | 1 | 2011 | 50 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2012 | 292 | 0.030 |
Why?
| | Mice, Inbred CBA | 1 | 2010 | 3 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 36 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2010 | 29 | 0.030 |
Why?
| | Blood Glucose | 1 | 2012 | 137 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 375 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 580 | 0.030 |
Why?
| | Heterozygote | 1 | 2011 | 115 | 0.030 |
Why?
| | Avidin | 1 | 2010 | 5 | 0.030 |
Why?
| | Protein Binding | 1 | 2010 | 155 | 0.030 |
Why?
| | Complement Activation | 1 | 2010 | 14 | 0.030 |
Why?
| | Asthma | 1 | 2013 | 182 | 0.020 |
Why?
| | Genes, Dominant | 1 | 2009 | 13 | 0.020 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2009 | 4 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 26 | 0.020 |
Why?
| | Family Health | 1 | 2009 | 38 | 0.020 |
Why?
| | Reference Values | 1 | 2009 | 260 | 0.020 |
Why?
| | Opportunistic Infections | 1 | 1989 | 14 | 0.020 |
Why?
| | 14-3-3 Proteins | 1 | 2008 | 6 | 0.020 |
Why?
| | HIV | 1 | 1989 | 89 | 0.020 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1989 | 100 | 0.020 |
Why?
| | Dialysis Solutions | 1 | 2008 | 6 | 0.020 |
Why?
| | Cytomegalovirus Infections | 1 | 1989 | 84 | 0.020 |
Why?
| | Globins | 2 | 1983 | 2 | 0.020 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 1983 | 4 | 0.020 |
Why?
| | RNA Splicing | 1 | 1983 | 12 | 0.020 |
Why?
| | Models, Genetic | 1 | 1983 | 37 | 0.020 |
Why?
| | Detergents | 1 | 2001 | 5 | 0.010 |
Why?
| | Gangliosides | 1 | 2001 | 9 | 0.010 |
Why?
| | Precipitin Tests | 1 | 2001 | 15 | 0.010 |
Why?
| | Agar | 1 | 2001 | 2 | 0.010 |
Why?
| | Thymidine | 1 | 2001 | 8 | 0.010 |
Why?
| | Genes, Viral | 1 | 2001 | 14 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 2001 | 33 | 0.010 |
Why?
| | Lipids | 1 | 2001 | 56 | 0.010 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2001 | 8 | 0.010 |
Why?
| | Okadaic Acid | 1 | 2001 | 6 | 0.010 |
Why?
| | Lac Operon | 1 | 2001 | 4 | 0.010 |
Why?
| | Intermediate Filaments | 1 | 2001 | 11 | 0.010 |
Why?
| | Gene Products, tat | 1 | 2001 | 4 | 0.010 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2001 | 16 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2001 | 46 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2001 | 160 | 0.010 |
Why?
| | Golgi Apparatus | 1 | 1999 | 7 | 0.010 |
Why?
| | GTP-Binding Proteins | 1 | 1999 | 15 | 0.010 |
Why?
| | Biological Transport | 1 | 1999 | 49 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 1999 | 37 | 0.010 |
Why?
| | Centrosome | 1 | 1998 | 1 | 0.010 |
Why?
| | Tubulin | 1 | 1998 | 19 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1999 | 129 | 0.010 |
Why?
| | Bradykinin | 1 | 1997 | 4 | 0.010 |
Why?
| | Epithelium | 1 | 1997 | 31 | 0.010 |
Why?
| | Mesoderm | 1 | 1997 | 21 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1997 | 512 | 0.010 |
Why?
| | Hippocampus | 1 | 1997 | 295 | 0.010 |
Why?
| | Neurons | 1 | 1997 | 407 | 0.010 |
Why?
| | Transcription, Genetic | 2 | 1983 | 125 | 0.010 |
Why?
| | Amylases | 1 | 1989 | 6 | 0.010 |
Why?
| | Lipase | 1 | 1989 | 6 | 0.010 |
Why?
| | Deoxyribonuclease BamHI | 1 | 1983 | 2 | 0.000 |
Why?
| | DNA Restriction Enzymes | 1 | 1983 | 6 | 0.000 |
Why?
| | Single-Strand Specific DNA and RNA Endonucleases | 1 | 1983 | 2 | 0.000 |
Why?
| | Endonucleases | 1 | 1983 | 2 | 0.000 |
Why?
| | Simian virus 40 | 1 | 1983 | 13 | 0.000 |
Why?
|
|
Reiser's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|